Efgartigimod non-responders after the first treatment cycle in generalized myasthenia gravis: a retrospective analysis of predictive factors. [PDF]
Front NeurolObjectiveThis study aimed to identify predictors of suboptimal response to efgartigimod in patients with generalized myasthenia gravis (gMG).MethodsIn this single-center retrospective study, 35 gMG patients treated with efgartigimod were categorized into
Niu Z +9 more
europepmc +3 more sources
Efgartigimod as Fast-Acting Rescue Therapy in Very Late-Onset Myasthenia Gravis [PDF]
Neurology and TherapyMyasthenic crisis (MC) is a potentially fatal complication of myasthenia gravis (MG), often requiring intensive care and rescue therapies such as intravenous immunoglobulin (IVIG) and corticosteroids.
Nicasio Rini +4 more
doaj +2 more sources
Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study. [PDF]
Front ImmunolBackgroundTarget-specific immunotherapies have been shown to effectively treat myasthenia gravis (MG) with less side effects. One such immunotherapy is efgartigimod, a neonatal Fc receptor antagonist, promotes degradation of pathogenic IgG antibodies ...
Hong Y +10 more
europepmc +3 more sources
Efgartigimod: First Approval [PDF]
Drugs, 2022 Efgartigimod (efgartigimod alfa-fcab, Vyvgart™) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. In December 2021, intravenous efgartigimod received its first approval in the USA for the treatment of generalized myasthenia gravis in adults who are anti ...
openaire +2 more sources
Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome [PDF]
, 2023 Stiff-person syndrome (SPS) is a rare autoimmune neurological disorder characterized by high titers of antibodies against glutamic acid decarboxylase (GAD) causing impaired GABAergic inhibitory neurotransmission.
Alonge, Paolo +6 more
core +1 more source
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial [PDF]
, 2022 Background: Pemphigus vulgaris and pemphigus foliaceus are potentially life-threatening autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal desmogleins.
De Simone, C
core +1 more source
Mapping the characteristics of network meta-analyses on antithrombotic therapies: an overview and critical appraisal [PDF]
, 2022 Objectives: A large number of network meta-analyses (NMAs) in the field of cardiac disease are available, yet the scientific literature lacks an updated straightforward synthesis of this evidence to ground the decision-making process. We aimed to map and
Mainka, F. +3 more
core +2 more sources
Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach. [PDF]
Muscle NerveABSTRACT Introduction/Aims Sex‐specific differences in myasthenia gravis (MG) are widely acknowledged, yet data on sex‐based outcomes of MG treatment are scarce. In accordance with Sex and Gender Equity in Research guidelines, this post hoc analysis assessed potential sex‐specific differences in treatment outcomes in acetylcholine receptor antibody ...
Hoffmann S +5 more
europepmc +2 more sources
Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis [PDF]
, 2023 Background and purpose: Therapy for myasthenia gravis (MG) is undergoing a profound change, with new treatments being tested. These include complement inhibitors and neonatal Fc receptor (FcRn) blockers.
Espinosa, Pablo Ezequiel +4 more
core +1 more source
Tatalaksana terkini pada miastenia gravis [PDF]
, 2022 Myasthenia gravis (MG) is a disorder of the neuromuscular junction that causes fluctuating muscle weakness. The etiology of this disease is due to the presence of antibodies that attack acetylcholine receptors on the postsynaptic membrane (autoimmune ...
Susanti, Lydia
core +1 more source